Abstract
Background: There are currently no guidelines concerning additional laboratory testing for specific autoantibodies among anti-nuclear antibody-negative sera with an anti-cytoplasmic staining pattern identified by indirect immunofluorescence assay. Moreover, few data are available that address this laboratory situation.
Methods: We performed specific autoantibody assays in 200 sera with an anti-nuclear antibody titer ≤1:32 and a cytoplasmic titer (undefined staining pattern) of ≥1:64, identified sequentially in the course of routine anti-nuclear antibody testing.
Results: A total of 85 sera (42.5%) were positive in one (n=57) or more (n=28) of the specific autoantibody tests performed. Autoantibodies identified were antimitochondrial (15%), antimicrosomal (13%), anti-neutrophil cytoplasmic (10%), anti-smooth muscle (6%), anti-parietal cell (4%), and extractable nuclear antigen (8.5%, including histones, SSA, SSB, Sm, Jo-1 or Scl-70). A positive result in one or more of these assays was more frequent at anti-cytoplasmic titers ≥1:1024 (77.8%) than at titers of 1:64–1:128 (7%) (χ2=25.3, p<0.001).
Conclusions: The present data demonstrate that undefined anti-cytoplasmic staining in anti-nuclear antibody-negative sera is associated with, although not necessarily caused by, a high frequency and wide range of specific autoantibodies. Further work is needed before specific recommendations can be made concerning follow-up in subjects with this laboratory finding.
Clin Chem Lab Med 2006;44:1283–6.
References
1. Solomon DH, Kavanaugh AJ, Schur PH, and the American College of Rheumatology and Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002; 47:434–44.10.1002/art.10561Search in Google Scholar
2. Von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic disease. Seminars Arthritis Rheum 1995; 24:323–58.10.1016/S0049-0172(95)80004-2Search in Google Scholar
3. Kavanaugh A, Tomar R, Reveille J, Solomon D, Homberger H. Guidelines for clinical use of the antinuclear antibody test for specific autoantibodies to nuclear antigens. Arch Pathol Lab Med 2000; 124:71–81.10.5858/2000-124-0071-GFCUOTSearch in Google Scholar PubMed
4. Peene I, Meheus L, Veys EM, De Keyser F. Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis 2001; 60:1131–6.10.1136/ard.60.12.1131Search in Google Scholar PubMed PubMed Central
5. Bossuyt X, Hendrickx A, Frans J. Antinuclear antibody titer and antibodies to extractable nuclear antigens. Arthritis Rheum 2005; 53:987–8.10.1002/art.21602Search in Google Scholar PubMed
6. Hoffman IE, Peene I, Veys EM, de Keyser F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem 2002; 48:2171–6.10.1093/clinchem/48.12.2171Search in Google Scholar
7. Bossuyt X, Luyckx A. Antibodies to extractable nuclear antigens in antinuclear antibody-negative samples. Clin Chem 2005; 51:2426–7.10.1373/clinchem.2005.058552Search in Google Scholar PubMed
8. Koh W-H, Dunphy J, Whyte J, Dixey J, McHugh NJ. Characterization of anti-cytoplasmic antibodies and their clinical associations. Ann Rheum Dis 1995; 54:269–73.10.1136/ard.54.4.269Search in Google Scholar PubMed PubMed Central
9. Keech CL, Gordon TP, McCluskey J. Cytoplasmic accumulation of the 52 kDa/SS-A nuclear autoantigen in transfected cell lines. J Autoimmunity 1995; 8:699–712.10.1006/jaut.1995.0052Search in Google Scholar PubMed
10. Shi MH, Tsui FW, Rubin LA. Cellular localization of the target structures recognized by the anti-Jo-1 antibody: immunofluorescence studies on cultured human myoblasts. J Rheumatol 1991; 18:252–8.Search in Google Scholar
11. Hardin JA, Rahn DR, Shen C, Lerner MR, Wolin SL, Rosa MD, et al. Antibodies from patients with connective tissue diseases bind specific subsets of cellular RNA-protein particles. J Clin Invest 1982; 70:141–7.10.1172/JCI110587Search in Google Scholar PubMed PubMed Central
12. Reichlin M, Arnett FC. Multiplicity of antibodies in myositis sera. Arthritis Rheum 1984; 27:1150–6.10.1002/art.1780271011Search in Google Scholar PubMed
13. Lems WF, van Schaardenburg D, van de Stadt RJ. Cytoplasmic staining, ANA negative status and ENA testing in rheumatic diseases. Ann Rheum Dis 1995; 54:779.10.1136/ard.54.9.779-cSearch in Google Scholar PubMed PubMed Central
14. Craig WY, Ledue TB, Johnson AM, Ritchie RF. The distribution of anti-nuclear antibodies in “normal” children and adults. J Rheumatol 1999; 26:914–9.Search in Google Scholar
15. Ritchie RF, Collins M, Ledue TB. A flexible, efficient, checkerboard immunoblot system for the detection and semiquantitation of specific antinuclear antibodies. J Clin Lab Anal 1992; 6:391–8.10.1002/jcla.1860060610Search in Google Scholar PubMed
16. Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity 2005; 38:93–103.10.1080/08916930400022673Search in Google Scholar PubMed
17. Sihvonen S, Korpela M, Mustila A, Mustonen J. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinuted peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. J Rheumatol 2005; 32:2089–94.Search in Google Scholar
18. Sinclair D. Clinical and laboratory aspects of thyroid autoantibodies. Ann Clin Biochem 2006; 43:173–83.10.1258/000456306776865043Search in Google Scholar PubMed
19. Berg PA, Klein R. Antimitochondrial antibodies in primary biliary cirrhosis and other disorders: definition and clinical relevance. Dig Dis 1992; 10:85–101.10.1159/000171347Search in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
